SCHEMBL4739581

SCHEMBL4739581

Nc1onc2cccc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 16/20 0.62
KIT P10721 12/20 0.62
FLT3 P36888 11/20 0.62
PDGFRB P09619 2/20 0.59
FLT1 P17948 4/20 0.55
TEK Q02763 3/20 0.55
CSF1R P07333 3/20 0.55
EPHB4 P54760 1/20 0.55
RIPK1 Q13546 3/20 0.54
FLT4 P35916 2/20 0.54
CHEK1 O14757 1/20 0.54
IKBKB O14920 1/20 0.54
JAK2 O60674 1/20 0.54
RPS6KA5 O75582 1/20 0.54
PRKD3 O94806 1/20 0.54
NTRK1 P04629 1/20 0.54
RPS6KB1 P23443 1/20 0.54
CDK2 P24941 1/20 0.54
MARK3 P27448 1/20 0.54
EPHA2 P29317 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4736486 0.93 KDR (0.72) KDRKITFLT3PDGFRBFLT1
SCHEMBL4737823 0.93 KDR (0.70) KDRKITFLT3PDGFRBFLT1
SCHEMBL1384952 0.86 KDR (0.74) KDRKITFLT3PDGFRBFLT1
SCHEMBL4735263 0.86 KDR (0.70) KDRKITFLT3PDGFRBFLT1
SCHEMBL5249583 0.85 KDR (0.73) KDRKITFLT3PDGFRBFLT1
SCHEMBL1382612 0.85 KDR (0.68) KDRKITFLT3PDGFRBFLT1
SCHEMBL1383101 0.84 KDR (0.67) KDRKITFLT3PDGFRBFLT1
SCHEMBL5362753 0.84 KDR (0.55) KDRKITFLT3PDGFRBFLT1
SCHEMBL1382188 0.84 KDR (0.70) KDRKITFLT3PDGFRBFLT1
SCHEMBL4736538 0.84 KDR (0.72) KDRKITFLT3PDGFRBFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO disclosed